Par Drugs & Chemicals Ltd
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Action(s) taken or orders passed
13 December 2025 - NSE appointed Kunvarji Finstock on Dec 12, 2025 per SEBI ex-parte interim order (Sept 15, 2025).
-
Copy of Newspaper Publication
14 November 2025 - Published standalone unaudited Q2/H1 results (ended Sep 30, 2025): total income Rs2,865.89 lakh, PAT Rs412.96 lakh.
-
Updates
13 November 2025 - Approved Q2/H1 FY26 unaudited results (30 Sep 2025): Qtr revenue Rs2,865.89L, profit Rs412.96L.
-
Outcome of Board Meeting
13 November 2025 - Board approved unaudited Q2/H1 (ended 30‑Sep‑2025) results: Q revenue ₹2,865.89L, H1 revenue ₹5,470.53L; limited review.
-
Outcome of Board Meeting
13 November 2025 - Unaudited Q2/H1 FY26 results: Q revenue Rs2,865.89L; H1 revenue Rs5,470.53L; Q PAT Rs412.96L; approved 13/11/2025.
Annual reports
Concalls
-
Jun 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Mar 2023TranscriptAI SummaryPPT
-
Mar 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Dec 2021TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Sep 2019TranscriptAI SummaryPPT
Business Overview:[1]
PACL manufactures Active Pharma Ingredients for domestic and exports markets, they have a portfolio of 15 APIs and 10 Fine Chemicals. It produces the entire range of products in the Antacid Molecules segment